Porcine circovirus 2 (PCV2) is the smallest autonomously replicating virus and thus defines the minimum amount 21 of genetic and biochemical information needed for infection. PCV2 infects nearly every tissue within its host, 22 and infections result in immunosuppression and subsequent death of the host. Infection is initiated via the 23 attachment of the PCV2 capsid to heparan sulfate and chondroitin sulfate B glycosaminoglycan (GAG) on the 24 surface of the cell. We demonstrate that the PCV2 capsid does not recognize the pyranose backbone of a GAG, 25 and solely interacts with the sulfates of GAG. We visualize the interaction between heparin sulfate, an analog 26 for heparan sulfate, and the PCV2 capsid using cryo--electron microscopy. The image reconstructions provide 27 the first example of an asymmetric distribution of heparin sulfate on the surface of a virus capsid. We 28 demonstrate that each subunit possesses six heparin sulfate binding sites, but binding at any site occludes 29 binding at the other five sites. The binding sites are defined by arginine, lysine, and polar amino acids. Mutation 30 of these arginine and lysine to alanine diminishes the binding capacity of the PCV2 to heparin sulfate. A third to 31 two--thirds of the binding sites (subunits) in each PCV2 is occupied by segments of one or multiple 12kDa heparin 32 sulfate chains -leaving the remaining subunits unliganded. We discuss the significance of the unliganded 33 subunits in the life cycle of PCV2. 34
48
Porcine circovirus 2 (PCV2) belongs to the Circovirus genus of the Circoviridae family (1). Members of this family 49 are non--enveloped viruses and possess a circular single stranded DNA (ssDNA) genome. Circoviruses are widely 50 distributed in nature and infect terrestrial, avian, and aquatic species in the animal kingdom (2). PCV2 infection 51 of swine causes Postweaning Multisystemic Wasting Syndrome (PMWS), which culminates in the 52 immunosuppression and death of the host from secondary infection. Autopsy of infected swine identifies PCV2 53 in nearly every tissue, indicating that it is a promiscuous virus (3). The promiscuous nature of PCV2 is further 54 exhibited by its ability to infect rodents and bovine in the wild, and BALB/c mice and human cells in the 55 laboratory (4--7). Remarkably, PCV2 is the smallest pathogenic virus capable of replicating in cells without the 56 need for additional viruses (8). The 1.7knt ambisense PCV2 genome encodes for a replicase (ORF1) responsible 57 for the rolling circle replication of the genome, a capsid protein (ORF2) responsible for forming the capsid, and 58 an ORF3 and ORF4 which may be responsible for apoptosis and pathogenic nature of PCV2 (9--13). The PCV2 59 capsid is a T=1 icosahedron composed of 60--copies of the capsid protein with a fold that is the canonical viral 60 jelly--roll first observed for the capsid protein of tobacco bushy stunt virus (14--16). 61
Here we provide the first structural mechanism of cellular recognition by porcine circovirus using a combination 62 of cryo--electron microcopy, biochemistry, and site directed mutagenesis. PCV2 has been shown to initiate 63 cellular infection via attachment to the glycosaminoglycans (GAGs) heparan sulfate and chondroitin sulfate B 64 (17) . Heparan sulfate and chondroitin sulfate B are ubiquitously expressed on mammalian cells and act as 65 attachment factors for a variety of macromolecules (18--20) . Heparan sulfate is a 30 to 70 kDa polysaccharide 66 composed of multiple sulfated domains (NS) separated by unsulfated domains (NA). The NS domains are 67 composed of the repeating disaccharide L--Iduronic acid (IdoA) and D--Glucosamine (GlcN) connected via a 1 4 68 linkage (Figure S1 ). IdoA and GlcN can be sulfated on carbon 2 while GlcN can be additionally sulfated on carbon 69 6. Three to eight disaccharides constitute an NS domain. The NS domain is similar to heparin sulfate, and 70 heparin sulfate is routinely used as a reagent to study the interaction between the NS domains of heparan 71 sulfate and their interacting partners. It should be noted that heparin sulfate could be additionally sulfated on 72 carbon 3 of GlcN. The NA domains are composed of the repeating disaccharide N--Acetyl--D--Glusomaine (GlcNAc) 73 and D--Glucoronic acid (GlcA). Two to twelve disaccharides constitute an NA domain (Figure S1) (19) .
Chondroitin sulfate B is composed of the repeating disaccharide N--Acetyl--Galactosamine (GalNAc) and IdoA 75 connected via a 1 3 linkage. GalNAc can be sulfated on carbon 4 (88% of pyranoses) and carbon 6 (5% or 76 pyranoses). IdoA can be sulfated on carbon 2 (7% or pyranoses) (20, 21) . 77
In this study we use heparin sulfate as an analog for studying the interaction between heparan sulfate and PCV2. 78
We address the following questions: 1) what chemical moieties of heparin sulfate interact with PCV2, 2) where 79 are the heparin sulfate binding sites on the PCV2, 3) does binding of heparin sulfate follow the icosahedral 80 symmetry of the capsid, and 4) does PCV2 undergo conformational changes upon binding of heparin sulfate? 81
We demonstrate that PCV2 does not distinguish the backbone pyranose of GAGs, rather it interacts with the 82 sulfates. We determine that each capsid protein possesses six heparin sulfate--binding sites, and show that 83 binding of heparin sulfate to the icosahedral capsid does not adhere to the capsid's symmetry. To our 84 knowledge, this is the first example of an asymmetric distribution of heparin sulfate on an icosahedral virus. 85
Furthermore, we show that the subunits do not undergo a conformational change upon binding heparin sulfate. 86
We discuss the possible role of unliganded subunits in the life cycle of PCV2. 87
Results: 88
The interaction between PCV2 and heparin sulfate is reversible and solely dictated by the sulfates 89
To study the interaction between heparan sulfate and PCV2 we used an in vitro binding assay that involves 90 interacting PCV2 with chromatography sorbent conjugated to 15kDa porcine intestinal mucosa heparin sulfate. 91
Heparin sulfate is routinely used as an analog of heparan sulfate for studying the interaction between 92 macromolecules and heparan sulfate -the cellular attachment factor to initiate PCV2 infection (17--19). We 93 determined the amount of time necessary to interact PCV2 virus like particles (VLP, GenBank: ACA51584.1) with 94 the sorbent to achieve the maximum amount of binding to heparin sulfate (Figure 1) . Two concentrations of 95 VLP were used (370 nM and 92 nM). Maximum binding occurred within 30 minutes for the lower concentration 96 of VLP, and within 3 hours for the higher concentration of VLP. We chose to use the higher concentration of 97 VLP (370 nM) for our subsequent studies because of its improved signal in our binding assays ( Figure S2) . We 98 then examined if the interaction was reversible by incubating the PCV2 bound sorbent with increasing 99 concentrations of 12kDa porcine intestinal mucosa heparin sulfate (Figure 1) . Elution of PCV2 from the sorbent 100 demonstrates that the interaction is reversible. 101
We employed a competition assay to determine the chemical moieties of GAGs that PCV2 recognizes for cellular 102 attachment. The assays determine the effectiveness of different ligands to compete with the mentioned 103 chromatography sorbent for binding PCV2 (Figure 1) . We examined the length and sulfation pattern of heparin 104 sulfate, the pyranose structure of the polysaccharide, and the branched nature of the polysaccharide chains. 105
The results demonstrate that while the efficiency of heparin sulfate dp6 (6--hexoses), dp10 (10--hexoses) and 106 dp20 (20--hexoses) to inhibit 15kDa heparin sulfate from binding to PCV2 increases, they are not nearly as 107 effective as dp36 (36--hexoses, 12kDa) heparin sulfate. A plausible explanation could be that there are multiple 108 weak binding sites on the PCV2 capsid, and that longer oligosaccharides have higher affinity to PCV2 because 109 they can bind to multiple sites concurrently. It has been shown that heparin sulfate fragments below dp18 are 110 helical, extended and rigid but become more bent with increasing size (22). Thus a dp6 and dp10 may bind to a 111 few binding sites on PCV2 that happen to follow their linear path, while the dp20 and dp36 heparin sulfate may 112 bend and bind to multiple sites on PCV2. 113
We then examined the ability of dextran sulfate (8kDa) to inhibit the interaction between PCV2 and the 114 chromatography sorbent. The dextran sulfate (8kDa) used in our studies is a highly branched polysaccharide, 115 with glucose repeating units connected via 1 4 linkages and branching points at 1 6. There are 2.8 sulfates 116 per glucose monomer for this product (personal communication with Alfa Aesar manufacturer). Dextran sulfate 117 is the ligand most efficient at inhibiting the interaction between PCV2 and 15kDa heparin sulfate (Figure 1) . 118
Dextran, in contrast, appears to slightly enhance the affinity of the VLP for the sorbent (data not shown). This is 119 likely due to dextran acting as a crowding agent (23). The ability of dextran sulfate to inhibit PCV2 from binding 120 heparin sulfate while dextran slightly enhancing the interaction suggest that the sulfates are sufficient for 121 binding to PCV2, and that the backbone polysaccharide does not interact with PCV2. 122
Finally, we examined the ability of 1.6MDa hyaluronic acid (HA) and 41kDa chondroitin sulfate B 123 glycosaminoglycans to inhibit the interaction between PCV2 and 15kDa heparin sulfate. Hyaluronic acid 124 demonstrates no affinity for PCV2 (Figure 1) . Hylauronic acid possesses a single carboxylate on each of its repeating disaccharide units. The hydrogen bonds formed within and between its repeating disaccharides 126 produce stiff helical polysaccharide chains that entangle at very low concentrations (24). Thus, the carboxylate, 127 stiff, and entangled properties of HA may not provide the appropriate interface for PCV2 to bind. Chrondroitin 128 sulfate B (CSB) demonstrates affinity for PCV2, but this affinity is much lower when compared to that of heparin 129 sulfate. This may be because of the lower sulfate content of CSB (an average of one sulfate per repeating 130 disaccharide) when compared to heparin sulfate (an average of three sulfates per repeating disaccharide). The 131 increased flexibility of CSB, as compared to the stiff nature of heparin sulfate, may allow CSB to bind additional 132 binding sites on the PCV2 capsid despite its low sulfate content (25). 133
Distribution of heparin sulfate on PCV2 does not follow the icosahedral symmetry of the capsid 134
To identify the binding sites of heparin sulfate on PCV2 we determined the cryo--EM image reconstruction of 135 PCV2 in the absence and presence of 12kDa (dp36) porcine intestinal mucosa heparin sulfate at pH 7. The 136 unliganded PCV2 image reconstruction, with imposed icosahedral symmetry, at a nominal resolution of 3.3Å is 137 similar to that reported by Liu et al. (Figure 2 ) (26). The atomic structures from the two reconstructions share 138 92.6% sequence identity and superpose with a root--mean--square deviation (RMSD) of 0.437Å. We generated 139 three cryo--EM image reconstructions of PCV2 in complex with heparin sulfate using a single data set. The image 140 reconstruction with imposed icosahedral symmetry at 2.8Å resolution is indistinguishable from the unliganded 141 image reconstruction described above, suggesting that the interaction between PCV2 and heparin sulfate may 142 not follow icosahedral symmetry, or that heparin sulfate was displaced during sample preparation. Similarly, 143 the refined atomic model is indistinguishable from the atomic model of the unliganed image reconstruction -the 144 RMSD for the two structures is 0.268Å. However, plotting the atomic displacement parameters (ADP) onto the 145 structures suggests that the heparin sulfate--liganded image reconstruction may be more dynamic (Figure 2) . 146
We then generated an asymmetric image reconstruction of the complex to 3.2Å resolution. Close inspection of 147 the image reconstruction at low contour levels identified molecular envelopes on the surface of PCV2 that could 148 not be accounted for by the PCV2 atomic coordinates; however, these envelopes are too weak to confidently 149 label as heparin sulfate. We postulated that if each subunit possessed multiple binding sites for heparin sulfate 150 but only one site could be occupied per subunit then each capsid might be composed of a unique combination of subunits liganded to heparin sulfate; thus, any averaging strategy could eliminate the molecular envelope of 152 heparin sulfate. To test this possibility, we employed the expand symmetry capability of Relion on the 153 alignment parameters from the image reconstruction where icosahedral symmetry was imposed. The 154 consequence of this strategy is to align the projections from all subunits to one another. We then used Frealign 155 to perform masked classification of a subunit (27--29). Seven of the ten classes identified molecular envelopes 156 that could not be seen in the original image reconstruction (Figure 3) . To generate a difference map for each 157 class average we subtracted from the class average an image reconstruction generated using the same number 158 of particles as the class average -these particles were randomly selected from the symmetry expanded data set. 159
The difference peaks were low--pass filtered to 7Å resolution to smoothen the shapes. 160
Mutation of Arg/Lys residues defining the heparin sulfate binding sites diminish the affinity of the capsid for 161
heparin sulfate 162 A total of seven difference peaks with strengths greater than 27--sigma are observed for the 10 classes (Figure 3) . 163
We used 27--sigma as the criteria to remove small and spurious difference density peaks. These peaks may 164 correspond to segments of the 12kDa heparin sulfate molecule incubated with PCV2. We note that the 165 amorphous shapes of these peaks may suggest that heparin sulfate uses multiple binding modes/poses to bind 166 to the capsid. Indeed, heparin sulfate is known to use multiple binding modes/poses to interact with proteins 167 (30). We modeled segments of heparin sulfate as rigid bodies into the difference peaks to see if the models 168 were chemically reasonable. We then examined if mutation of the Arg and Lys amino acids that interact with 169 the sulfates in our models diminished the mutant VLP's affinity for heparin sulfate. Class 1 (11% of subunits) 170 does not possess a difference peak and thus represents an unliganded subunit. The difference peak for class 2 171 (9% of subunits) is located near Arg73 and Lys132 of the same subunit. Mutation of Arg73 to Ala diminishes 172 capsid--heparin sulfate affinity to 63% of wild type, whereas mutation of Lys132 to Ala abolishes capsid assembly. 173
A four--hexose segment of heparin sulfate can be modeled into this difference peak (Figure 4) . The difference 174 peak for class 3 (9% of subunits) is located near Lys58 and Arg59, but is too small to accommodate heparin 175 sulfate; thus, we interpret this class to represent an unliganded subunit. The difference peak for class 4 (11% of 176 subunits) is near Arg89, and next to the icosahedral 2--fold axis of symmetry. Mutation of Arg89 to Ala diminishes capsid--heparin sulfate affinity to 48% of wild type. A three--hexose segment of heparin sulfate can be 178 modeled into this density (Figure 4) . The difference peak for class 5 (10% of subunits) is extremely week; thus, 179 we interpret this class to represent an unliganded subunit. The difference peak for class 6 (9% of subunits) runs 180 between adjacent facets. It is located near Arg186 and Lys227 of the adjacent subunit. Mutation of Arg186 to 181 Ala diminishes the capsid--heparin sulfate affinity to 76% of wild type, whereas mutation of Lys227 to Ala 182 abolishes capsid assembly. A five--hexose segment of heparin sulfate can be modeled into this difference peak. 183
A number of hydrogen bonds are possible between the sulfates of heparin and the side chains of Thr131, 184
Tyr138, and Ser86 (Figure 4) . The difference peak for class 7 (14% of subunits) is distal to Arg/Lys, but a five--185 hexose segment of heparin sulfate modeled into the difference peak suggests that hydrogen bonds can form 186 between the sulfates of heparin and the side chains of Asn128, Gln188, and the three Tyr173 at the icosahedral 187 3--fold axis (Figure 4) . The difference peak for class 8 (12% of subunits) is also very weak; therefore, we interpret 188 this class as an unliganded subunit. The difference peak for class 9 (7% of subunits) is located near Arg73 and 189
Lys132 of a subunit. A three--hexose segment of heparin sulfate modeled into this difference peaks can form 190 additional hydrogen bonds between heparin's sulfates and the side chains of Asn128 and Gln188 (Figure 4) . The 191 difference peak for class 10 (8% of subunits) is located near the icosahedral 5--fold axis, and surrounded by Lys58 192 and Arg59 of one subunit and Lys63 of a neighboring subunit. A sulfate was also observed at this location in the 193 crystal structure of PCV2 (31). Mutation of either Lys58 or Arg59 to Ala diminishes PCV2--heparin sulfate 194 interaction to 65%, while mutation of Lys63 diminishes the affinity to 38%. A two--hexose segment of heparin 195 sulfate can be modeled into this density (Figure 4) . 196
Occupied heparin binding sites cluster on the surface of VLPs 197
We used Relion's symmetry operators to map the class that each subunit is assigned to onto the VLP to generate 198 composite molecular envelopes representing each VLP bound to heparin sulfate ( for us to refine the atomic models with little ambiguity. Refining the atomic model, generated from the image 205 reconstruction with imposed icosahedral symmetry, into each of the seven classes does not identify any 206 significant movement that could be associated with a conformational change upon binding of heparin sulfate. 207
The largest RMSD between two subunits is 0.313Å. 208
Discussion 209
Heparin sulfate is routinely used as an analog of heparan sulfate to study protein--heparan sulfate interaction 210 (19) . Our biochemical studies demonstrate that the interaction between PCV2 capsid and heparin sulfate is 211 heavily reliant on the length of the polysaccharide chain, with longer chains exhibiting a greater affinity for the 212 capsid. This suggests that heparin sulfate may bind to the capsid via multiple weak binding sites. Our 213 biochemical data further suggests that the interaction is solely driven by the sulfate moieties on heparin sulfate PCV2 infection of PK--15 cells by inhibiting capsid disassembly in the endosome--lysosome system -suggesting 234 that digestion of PCV2 subunits by a cellular endosome--lysosome serine protease may be necessary for 235 infection. Indeed, the PROSPER Protease specificity prediction server identifies a number of Cathepsin G (a 236 lysosomal serine protease) digestion sites in the capsid protein sequence. Two of these sites are on the surface 237 of the capsid and become inaccessible when heparin sulfate is modeled into the difference peaks identified in 238 this study. The attachment of heparan sulfate to a PCV2 subunit may create a steric hindrance for such a 239 protease to help disassemble the capsid; thus, it would make sense for some subunits to be unliganded to 240 heparan sulfate so that the subunits could be hydrolyzed by such a serine protease. 241
In conclusion, we demonstrate that PCV2 capsids recognize the sulfates of GAGs rather than the backbone 242 pyranoses, that subunits possess six binding sites capable of binding heparin sulfate but only one site is occupied 243 per subunit, that not all binding sites are occupied, that the binding of heparin sulfate to the capsid does not 244 adhere to the icosahedral symmetry of the capsid, and that binding of heparin does not induce a conformational 245 change in the capsid but may affect its dynamics. 246
Materials and Methods 248

PCV2 VLP expression and purification 249
The codon sequence for the PCV2 capsid protein (GeneBank ACN59889.1) was optimized by GenScript for 250
Baculovirus expression system. GenScript also generated the Baculovirus stock used in these studies. 251
Trichoplusia ni insect cells were propagated in ESF921 medium (Expression System) and infected with the 252 Baculovirus at an MOI of 0.1. Cells were grown for 5 days till 70% had lysed according to Trypan blue staining. 20°C. The sorbent was processed as described above. 283
Elution assays: VLP bound to HyperD TM M sorbent (as described above) was incubated with increasing 284 concentrations of porcine intestinal mucosa heparin sulfate (see below) for 3 hours at 20°C. The bound VLP was 285 quantitated as described above. 286
Competition assays: GAG reagents were incubated with PCV2 at 20°C for 3h prior to performing the binding 287 assay. VLP and GAG were incubated for 3h with the HyperD TM M sorbent. The sorbent was processed as 288 described above. 289
Glycosaminoglycans and polysaccharide source 290
Heparin sulfate oligosaccharides (HO06, HO10, HO20) , and chondroitin sulfate B (DS01) were purchased from 291
Galen laboratories, and dissolved in water. Porcine intestinal mucosa heparin sulfate (average molecular weight 292 12kDa) was purchased from JT Baker, hyaluronic acid and dextran sulfate 8kDa from Alfa Aesar. All reagents 293 were used within 48 hours after being dissolved in the VLP dialysis buffer. Concentrations were calculated 294 based on the disaccharide molecular weight of 659 g/mol for heparin sulfate, 551 g/mol for chondroitin sulfate 295
Ultrathin carbon film on Lacey Carbon support film (TedPella, 01824) were used for cryo--electron microscopy. 298
Grids were glow discharged using a PELCO easiGlow TM for 30 seconds. Samples (4µl) were adsorbed to the grid 299 for 15 seconds, blotted with a force of 2 for 6 seconds, and plunge frozen into liquid ethane using an FEI Mark IV 300 vitrobot. Data for the unliganded PCV2 was collected using a side entry FEI Titan Halo with the Leginon software 301 (38) . Images were collected at a calibrated magnification of 45,871x on a Gatan K2 camera operating in 302 counting mode. Cryo--EM grids for the PCV2 liganded to heparin sulfate were prepared by incubating 20µl of the 303 VLP with 7µl of 60mg/ml 12 kDa heparin sulfate for 3 hours. The mixture was then incubated with 2µl of 304 HyperD TM M sorbent for 3 hours at 20°C on a revolver to remove VLP that was not bound to heparin sulfate. 305
Cryo--EM grids were prepared as described for the unliganded PCV2. Data for the heparin sulfate liganded PCV2 306 was collected on a Titan Krios with the Leginon software. Images were collected at a calibrated magnification of 307 45,871x on a Gatan K2 camera that follows a GIF Quantum Energy Filter with a slit width of 15eV. Data 308 collection parameters for both data is reported in Table 1 . 309
Motion correction was performed using the MotionCor2 package (39). The first frame of each movie was 310 discarded during the alignment. With the exception of a patch 5 option, the default options were used for the 311 alignment and dose weighting. Particles were automatically detected using Gautomatch and per--particle 312 contrast transfer function (CTF) estimation was performed on the aligned micrographs using Gctf (40). Briefly, 313 particles were extracted from the dose--weighted micrographs using the coordinates identified by Gautomatch. 314
Reference free 2D classification with a diameter of 250Å and default Relion 2.0 parameters were used to discard 315 bad particles (29). The PCV2 crystal structure (PDB entry 3R0R) was used to generate a 60Å resolution initial 316 model for 3D classification with default Relion 2.0 parameters and C1 symmetry. The 3D class with the highest 317 resolution image reconstruction was used for further refinement using I1 symmetry. Default parameters were 318 used for the refinement and postprocessing. 319
The procedure for processing the PCV2 liganded to heparin sulfate data is identical to that of the unliganded 320 data; however, an additional 3D refinement was performed using C1 symmetry following 3D classification. For 321 the masked classification, the refinement parameters for 3D refinement with I1 symmetry of 13,600 particles were further processed using the relion_particle_symmetry_expand program of Relion 2.0. A 25Å resolution 323 volume of a subunit was generated using the molmap function of UCSF Chimera (41) . The mask was manually 324 moved outward to include area peripheral to the capsid in case heparin sulfate may be present on the surface of 325 the capsid. The alignment parameters and images were converted to a format for Frealign using the 326 relion_preprocess function of Relion and the conversion script provided by the Frealign authors. Twenty rounds 327 of masked classification (10 classes) without alignment were performed (28, 42). 328
Difference maps were calculated using the vop function of UCSF Chimera (41). The image reconstruction from 329 each class was subtracted from an image reconstruction generated using the same number of particles 330 randomly selected from the entire data. The image reconstructions from randomly selected particles were 331 visually indistinguishable from the icosahedrally averaged image reconstruction. 332
The difference peaks for each class were mapped onto the symmetrized image reconstruction using the 333 symmetry operators (I1) of Relion used during the symmetry expansion process. These composite volumes were 334 generated and visualized using the UCSF Chimera package. 335
Structure refinement 336
The reported crystal structure of PCV2 (31) was manually docked into the symmetrized image reconstructions 337 using UCSF Chimera. The resulting coordinates were iteratively refined using phenix.real_space_refine with 338 noncrystallographic symmetry constraints applied, and manual fitting with Coot (43, 44). 339
Hepairn sulfate molecules (PDB entries 3IRI, 3IRJ, 3IRK, and 3IRL) were treated as rigid bodies and manually 340 fitted into the difference peaks of the six classes described above. The capsid protein subunit pertaining to 341 these molecular envelopes were further refined using manual fitting and phenix.real_space_refine, without 342 noncrystallocgraphic symmetry. 343
Mutagenesis and binding efficiency 344
Single point mutants of the PCV2 capsid were made to the consensus sequence construct described in Khayat et 345 al. 2011 . Briefly, this construct possesses a hexahistidine and a thrombin cleavage site at the N--terminus in lieu 346 of the forty--two amino acids in the GeneBank ACN59889.1. The remaining amino acid sequence is identical.
Mutations were made using the New England Biolabs Inc. site directed mutagenesis kit. Sequences were 348 confirmed using the services of Genewiz. Proteins were purified as previously described (45). Virus like particles 349 (VLPs) were assembled by mixing equal volumes of the capsid protein at 37 µM with 12% polyethylene glycol 350 3350, 5% isopropanol, and 0.6M Ammonium Citrate pH 5.0 at 4°C overnight. VLPs form crystals in this solution. 351
The crystals were pelleted via centrifugation at 14,000xg for 10minutes at 4°C. The pellet was suspended in The image reconstructions and atomic coordinates have been deposited into the EMDB and PDB respectively. 372 Accession codes (EMDB/PDB) are: Unliganded image reconstruction (8939/6DZU); symmetrized liganded image 373 reconstruction (8969/6E2R); Class 02 (8970/6E2X); Class 04 (8971/6E2Z); Class 06 (8972/6E30); Class 07 374 (8973/6E32); Class 09 (8974/6E34); Class 10 (8975/6E39). 375 higher ADP, and thus a more dynamic structrue. Images generated with UCSF Chimera. 479 heparan sulfate glycosaminoglycan chain. The NS domain is composed of 3--8 repeating disaccharides, and the 527 NA domain is composed of 2--12 repeating disaccharide. Bottom) Chemical structure of the heparan sulfate and 528
Figure Legends
heparin sulfate repeating disaccharides. The repeating disaccharide of the heparan sulfate NS domain is similar 529
to the repeating disaccharide of heparin sulfate. 530 531 532 Figure S2 . SDS--PAGE densitometry of PCV2 VLP heparin binding interaction. Images represent the interaction 534 between PCV2 VLP and HyperD TM chromatography sorbent. The contrast of each digitized SDS--PAGE was scaled 535 to enhance the signal for visualization. This modification does not affect the intensity reported by the Image 536
Studio TM software used for the analysis. The numbers above each band represent the intensity corrected by 537 background subtraction within each box. A) Linear response curve of the LI--CORR Odyssey CLX to increasing 538 amount of PCV2 capsid protein, indicating that intensity is directly correlated to protein content. B) Binding 539 kinetics of 370 nM and 97 nM VLP demonstrating that the signal from 370 nM produces a robust readout ( Figure  540 1A). Elution of VLP from the sorbent with increasing heparin concentration ( Figure 1B ). Binding efficiency of in 541
vitro assembled wild--type, K58A, R59A, K63A, R73A, R89A, and R186A capsids (Figure 4 ). GAG competition assay 542
representatives of: C) 6--hexose, D) 10--hexose, E) 20--hexose, F) 36--hexose heparin, G) chondroitin sulfate B, H) 543 dextran sulfate 8kDa, and I) hyaluronic acid. The plots for panels C--I are representatives of Figure 1C . 544 545 
